Mallinckrodt Enrolls First Patient in Phase 1 Study of ExpressGraft™C9T1 Skin Tissue

Mallinckrodt logoSTAINES-UPON-THAMES, United Kingdom, Feb. 14, 2018 /PRNewswire/ — Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today confirmed enrollment of the first patient in the company’s Phase 1 study assessing the safety and tolerability of ExpressGraft™C9T1…

PR NEWSWIRE

About M Fund

SITE ADMIN